{"filing":{"accession_number":"0001628280-26-050775","cik":"0001157601","ticker":"MDGL","company_name":"MADRIGAL PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"mdgl-20260730.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1157601/000162828026050775/mdgl-20260730.htm"},"events":[{"id":22031,"run_id":19899,"accession_number":"0001628280-26-050775","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a straightforward earnings release disclosing Madrigal's second-quarter 2026 financial results. The Item 2.02 filing announces quarterly net revenues of $364.3 million (71% YoY growth), net loss of $57.9 million, and cash position of $838.9 million as of June 30, 2026, with the full press release furnished as Exhibit 99.1. The disclosure is material as it reports significant revenue growth and operational metrics for a publicly traded biopharmaceutical company.","company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":21837,"accession_number":"0001628280-26-050775","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a straightforward earnings release disclosing Madrigal's second-quarter 2026 financial results. The Item 2.02 filing announces quarterly net revenues of $364.3 million (71% YoY growth), net loss of $57.9 million, and cash position of $838.9 million as of June 30, 2026, with the full press release furnished as Exhibit 99.1. The disclosure is material as it reports significant revenue growth and operational metrics for a publicly traded biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T11:06:50.900636+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21837,"accession_number":"0001628280-26-050775","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a straightforward earnings release disclosing Madrigal's second-quarter 2026 financial results. The Item 2.02 filing announces quarterly net revenues of $364.3 million (71% YoY growth), net loss of $57.9 million, and cash position of $838.9 million as of June 30, 2026, with the full press release furnished as Exhibit 99.1. The disclosure is material as it reports significant revenue growth and operational metrics for a publicly traded biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T11:06:50.900636+00:00","company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","filing_date":"2026-07-30"}]}